Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective

April 28th 2025

Panelists discuss how conversations with patients about treatment options have become more complex and nuanced, requiring thorough explanation of efficacy data and adverse effects while adapting to each patient’s level of understanding and involvement.

Combination Therapy: A New Frontline Standard in the Treatment of EGFR-Mutant NSCLC

April 28th 2025

Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer has evolved with new combination therapies like osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA) challenging osimertinib monotherapy as the standard of care.

Zoldonrasib Shows Encouraging Early Antitumor Activity in KRAS G12D–Mutated NSCLC

April 27th 2025

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 4/20

April 26th 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

April 25th 2025

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

Optune Lua Granted CE Mark Approval in EU for Metastatic NSCLC

April 24th 2025

A CE Mark has been granted to Optune Lua concurrent with immune checkpoint inhibitors or docetaxel for patients with metastatic non–small cell lung cancer.

First-Line Ivonescimab Plus Chemo Improves PFS in Advanced Squamous NSCLC

April 23rd 2025

Ivonescimab plus chemotherapy met the primary PFS end point vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Updated ASCO Living Guidelines Highlight Need for Timely, Patient-Friendly Communication in Stage IV NSCLC

April 23rd 2025

Fawzi F Abu Rous, MD, discusses updates to the ASCO Living Guidelines for the management of stage IV non–small cell lung cancer with driver alterations.

Comprehensive Biomarker Testing in Early-Stage NSCLC: Identifying Gaps, Challenges, and Strategies for Improvement

April 23rd 2025

Panelists discuss how comprehensive biomarker testing in early-stage disease settings provides crucial molecular insights that guide surgical planning and inform critical decisions about neoadjuvant, perioperative, and adjuvant treatment strategies.

Optimizing Molecular Testing, Diagnosis, and Workflow in Early-Stage NSCLC Through Multidisciplinary Collaboration

April 23rd 2025

Panelists discuss how collaboration between pathologists, oncologists, and pulmonologists is essential for timely next-generation sequencing (NGS) testing in early-stage non–small cell lung cancer (NSCLC), emphasizing that molecular testing should ideally be ordered at diagnosis with prioritization of EGFR, ALK, ROS1, BRAF, MET, KRAS, RET, and NTRK biomarkers to guide treatment decisions before surgical intervention.

Health Canada Approves Pembrolizumab/Chemotherapy for Unresectable, Advanced or Metastatic Pleural Mesothelioma

April 22nd 2025

Pembrolizumab/chemotherapy was approved by Health Canada for the treatment of patients with unresectable advanced or metastatic pleural mesothelioma.

Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung

April 21st 2025

Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.

Personalized Therapy, Surgical Staging, and Expanded Screening Guidelines Drive Progress in NSCLC

April 20th 2025

Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.

Tarlatamab and Durvalumab Enhance the SCLC Immunotherapy Paradigm

April 18th 2025

Isabel Preeshagul, DO, MBS, discusses frontline treatment selection for patients with SCLC and significant FDA approvals in this disease.

Optimizing Tissue Biopsy and Disease Staging in Early-Stage NSCLC

April 16th 2025

Panelists discuss how medical professionals frequently encounter tissue adequacy challenges in comprehensive genomic profiling for early-stage non–small cell lung cancer (NSCLC), employing strategies such as optimized biopsy techniques, efficient tissue triage protocols, and complementary liquid biopsies to ensure sufficient material for complete molecular analysis.

CCTG BR.31 Data Show Adjuvant Durvalumab Does Not Alter Relapse Frequency or Patterns in Resected NSCLC

April 16th 2025

Adjuvant durvalumab was not associated with a reduction in the frequency of relapse in NSCLC.

Comprehensive Molecular Testing in Early-Stage NSCLC: Best Practices and Multidisciplinary Strategies

April 16th 2025

Panelists discuss how medical professionals currently approach molecular testing in early-stage non–small cell lung cancer (NSCLC) through comprehensive biomarker analysis, including targeted next-generation sequencing (NGS), to identify actionable mutations that guide adjuvant therapy decisions and improve patient outcomes.

Enhanced Dermatologic AE Prophylaxis Is Effective in EGFR-Mutated Advanced NSCLC

April 15th 2025

Enhanced dermatologic management lowered rates of dermatologic AEs during first-line amivantamab/lazertinib treatment for EGFR-mutated advanced NSCLC.

Dr Abu Rous on the Identification of Clinically Actionable Biomarkers in Squamous Cell Carcinoma of the Lung

April 14th 2025

Fawzi F Abu Rous, MD, discusses the need for reliable predictive biomarkers for therapeutic development in squamous cell carcinoma of the lung.

The OncFive: Top Oncology Articles for the Week of 4/6

April 12th 2025

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.